TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Prediction and diagnosis of ectopic pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Hamilton Rating Scale for Depression-17 item version (HRSD-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measurement accuracy of MRE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Glucose Self-monitoring Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of 90-day complications
Endpoint domain: Adverse events/effects
Primary endpoint: Deposition of radiolabelled OligoG in the lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of FI Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Side branch loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PCI related myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease activity score (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total heartburn relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Critical closing pressure of the upper airway (Pcrit)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Burden Assessment Scale (BAS)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Family Assessment Device - Global Functioning Scale (FAD-GFS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects With Antibody Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in microvesicle particles (MVP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability to participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility and acceptability to research staff
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Adverse events related to ApoGraft product
Endpoint domain: Adverse events/effects
Primary endpoint: Number of touches at the upper limb closed kinetic chain test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a favourable outcome
Endpoint domain: Mortality/survival
Primary endpoint: Lung deposition of tobramycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCLA Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: % of women with wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Tendon Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Victorian Institute of Sport Assessment - Achilles (VISA-A) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Victorian Institute of Sport Assessment - Patellar Tendon (VISA-P) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tolerability and potential adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Achievement rate of target nutritional goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: All cause remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half life of Carboxyhemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in plasmatic concentration of milk-derived peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes from baseline of insulin plasmatic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes from baseline of glucose-dependent insulinotropic peptide (GIP) plasmatic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: discrimination index of prediction model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from tumor progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects experiencing Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Return to regular work or school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maintenance of work/school attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Quality of work functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change score from baseline of the ADHD-RS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in circulating microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of PET/CT image
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Combined Score (DCS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mini RQLQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Final Emergency Department Disposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause bowel leaks after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Adaptive Functioning (SOFAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Adaptive Functioning (SFS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Adaptive Functioning (MCAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Cardiotoxicity Development Risk Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Early Detection of Cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum lactate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG record
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events after injection of fluorine F 18 d-FMAU
Endpoint domain: Adverse events/effects
Primary endpoint: Fluorine F 18 d-FMAU uptake change in tumors post-therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent change in creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: percent change in blood urea nitrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in the development of psychotic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Coronary artery endothelial responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive Skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Global Cognitive Function Using Mini Mental State Examination Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of myocardial infarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of strokes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet counts ≥ 30 x 10^9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Musculoskeletal Pain Intensity and Interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of complicated appendicitis
Endpoint domain: Mortality/survival
Primary endpoint: Change in CAARMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Steps Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Physical Activity in Minutes Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive performance of postoperative laryngeal ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of sensors used per week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average number of hours of use per sensor
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of sensors per week that fail to calibrate
Endpoint domain: Adverse events/effects
Primary endpoint: American Shoulder and Elbow Surgeons score (ASES)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Morphological response to treatment
Endpoint domain: Physiological/clinical
Primary endpoint: Clearance of Cerebral Spinal Fluid (CSF) blasts
Endpoint domain: Physiological/clinical
Primary endpoint: Intestinal Symptoms Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Limb volume measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circumferential wrist measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circumferential forearm measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extra-cellular fluid measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Regadenoson Stress-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of Regadenoson Stress-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in the 6 Minute Walk Test (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Report of Diabetic Ketoacidosis (DKA) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Report of Severe Hypoglycemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Report of Hospitalization Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time spent on biological motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the internet-based self-help program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: status of tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: patients performance status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Antibiotics Exposure Days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fluoroscopic lead displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Response to Neoadjuvant Erlotinib Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of Cincinnati prehospital stroke severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Iron pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Angiographic evidence of plaque shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight in Kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI in Kg/m²
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Glucose (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mortality (all causes)
Endpoint domain: Mortality/survival
Primary endpoint: Mortality (vascular causes)
Endpoint domain: Mortality/survival
Primary endpoint: Mean 24 Hour Ambulatory Systolic Blood Pressure (maSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of neuropsychiatric and central nervous system (CNS) toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Serious and Non-serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of adverse clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in self-efficacy in condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Post Op Atrial Fibrillation
Endpoint domain: Adverse events/effects
Primary endpoint: proBNP (Serum) Between Groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak percent change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase in serum potassium ≥6.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Compliance with early medical care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Patients Achieving Target SF ≤ 100 μg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue analysis results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of re-operation for adjacent segment disease
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limiting Toxicity, DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose, MTD
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of gemcitabine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Child's Anxiety level (RCMAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Child's Emotional/Behavioral Status (CBCL)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depression scale (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Responder in frequency of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of ACF in the left colon and rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Patients with Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Surgical Site infections (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Urinary tract infections (UTI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Nausea and/or Vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Categorical findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of combined CRP-PCT-WBC trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary calcium to creatinine ratio (UCa/Cr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary crystals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-acting Injection (LAI) Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: concentration of HMGB1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe acute non-genitourinary side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Area Under The Concentration Versus Time Curve (AUC(0-infinity)) for Ondansetron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) for Ondansetron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of social precariousness
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change from Baseline return to work issues incidence at 60 months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from Baseline cognitive problems incidence at 60 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prognosis of three port vs four port laparoscopic cholecystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Energy and protein consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet quality as measured by Healthy Eating Index (HEI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in performance level (Karnofsky percentage)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent of Subjects With PASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: cumulative toxicity score
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of molecular Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jankovic Rating Scale (JRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores from questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HF readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time reduction of current parametric reconstruction protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Olerud-Molander Ankle Score (OMAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of embryo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Grafted Skin Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: elevated PR/CR ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death and life- or health-threatening condition
Endpoint domain: Mortality/survival
Primary endpoint: Perineal-cephalic distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of Sum of NRS-11 Abdominal Pain and Bloating/Flatulence Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Seroprotected Subjects for Anti-polyribosyl Ribitol Phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seropositive Subjects for Anti-pertussis, Anti-filamentous Haemagglutinin and Anti-pertactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: First pass success rate on prehospital tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Worst Pain rating of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure Reduction Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Maximum observed plasma concentration of GSK2336805
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve of GSK2336805
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The actual sampling time to reach the maximum observed plasma concentration of GSK2336805
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gingival crevicular fluid levels of prostaglandin E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in gingival crevicular fluid levels of interleukin-1beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Worst Itching Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dyspnea index score (mMRC score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in expression of androgen receptor abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of performing SRP
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time required to perform SRP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of cases identified as having excessive bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women who experience a serious adverse event due to excessive bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Level of acceptability and satisfaction with using misoprostol as first-aid option to treat excessive bleeding
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nitric oxide-mediated macro (arterial) circulatory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Responder rate at Day 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes